Un jugement récent a déterminé que la technologie HCR™ RNA-ISH de Molecular Instruments ne contrevenait pas à deux brevets d’Advanced Cell Diagnostics.

Written by Emily J. Thompson, Senior Investment Analyst

Source: Businesswire

Updated: Nov 25 2025

0mins

Source: Businesswire

Legal Victory for Molecular Instruments: The Unified Patent Court of the European Union ruled that Molecular Instruments' HCR™ RNA-ISH technology does not infringe on two patents held by Advanced Cell Diagnostics, dismissing the allegations made in a 2024 lawsuit.
Previous Ruling in the UK: This ruling follows a decision by the High Court of England and Wales in April 2024, which invalidated the same patents based on overwhelming evidence of obviousness.
Impact on Scientific Research: Dr. Harry Choi, CEO of Molecular Instruments, emphasized that these legal victories are crucial for maintaining access to their innovative imaging platform for European scientists, which is essential for various research projects.
About HCR™ RNA-ISH Technology: The HCR™ RNA-ISH platform utilizes dynamic nanotechnology for RNA imaging, allowing for high-resolution, multiplexed analysis while preserving sample integrity, making it a leading choice in molecular imaging applications.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free